Oklahoma Medical Research Foundation
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1946-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.omrf.org
Clinical Trials
13
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT04726553
- Locations
- 🇺🇸
Yale University Medical Center, New Haven, Connecticut, United States
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸New York University Medical Center, New York, New York, United States
Antecedent Metabolic Health and Metformin Aging Study
- Conditions
- Chronic DiseaseInsulin ResistanceInsulin SensitivityMitochondriaAging
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 101
- Registration Number
- NCT04264897
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma Shared Clinical and Translational Resources, Oklahoma City, Oklahoma, United States
🇺🇸University of Wisconsin-Madison, Madison, Wisconsin, United States
MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE
- Conditions
- Systemic Lupus Erythematosus Arthritis
- Interventions
- Drug: Placebos
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 9
- Registration Number
- NCT03355482
- Locations
- 🇺🇸
Access Health, Las Vegas, Nevada, United States
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 66
- Registration Number
- NCT02270957
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT02270970
- Locations
- 🇺🇸
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
- Prev
- 1
- 2
- 3
- Next